Nanollose Limited (NC6.AX)
AUD 0.04
(0.0%)
AUD 0.04
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -96.22 Thousand AUD | 82.07% |
| 2023 | -536.72 Thousand AUD | 65.33% |
| 2022 | -1.54 Million AUD | 47.85% |
| 2021 | -2.96 Million AUD | -280.1% |
| 2020 | -781.03 Thousand AUD | 30.43% |
| 2019 | -1.12 Million AUD | 62.33% |
| 2018 | -2.98 Million AUD | 30.6% |
| 2017 | -4.29 Million AUD | -75623.0% |
| 2016 | 5686.00 AUD | 149.17% |
| 2015 | 2282.00 AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -76.22 Thousand AUD | 85.8% |
| 2024 Q2 | -304.73 Thousand AUD | 43.22% |
| 2024 Q4 | -96.22 Thousand AUD | 68.42% |
| 2023 Q2 | -753.54 Thousand AUD | 0.0% |
| 2023 FY | -536.72 Thousand AUD | 65.33% |
| 2023 Q4 | -536.72 Thousand AUD | 0.0% |
| 2022 FY | -1.54 Million AUD | 47.85% |
| 2022 Q2 | -2.1 Million AUD | 0.0% |
| 2022 Q4 | -1.54 Million AUD | 0.0% |
| 2021 Q2 | -526.03 Thousand AUD | 0.0% |
| 2021 FY | -2.96 Million AUD | -280.1% |
| 2021 Q4 | -2.96 Million AUD | 0.0% |
| 2020 Q4 | -781.03 Thousand AUD | 0.0% |
| 2020 FY | -781.03 Thousand AUD | 30.43% |
| 2020 Q2 | -534.5 Thousand AUD | 0.0% |
| 2019 Q4 | -1.12 Million AUD | 0.0% |
| 2019 FY | -1.12 Million AUD | 62.33% |
| 2019 Q2 | -2.04 Million AUD | 0.0% |
| 2018 Q4 | -2.98 Million AUD | 0.0% |
| 2018 FY | -2.98 Million AUD | 30.6% |
| 2018 Q2 | -3.8 Million AUD | 0.0% |
| 2017 Q1 | - AUD | 0.0% |
| 2017 FY | -4.29 Million AUD | -75623.0% |
| 2017 Q4 | 20.76 Thousand AUD | 151.63% |
| 2017 Q3 | -40.21 Thousand AUD | 0.0% |
| 2016 FY | 5686.00 AUD | 149.17% |
| 2015 FY | 2282.00 AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | 88.615% |
| Acrux Limited | -1.45 Million AUD | 93.4% |
| Actinogen Medical Limited | -9.13 Million AUD | 98.946% |
| AnteoTech Limited | -5 Million AUD | 98.076% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 99.395% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 99.243% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 90.202% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 99.229% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 94.723% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 98.194% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | 86.439% |
| Biome Australia Limited | -1.56 Million AUD | 93.843% |
| Biotron Limited | -386.06 Thousand AUD | 75.076% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 99.879% |
| BTC Health Limited | -2.02 Million AUD | 95.241% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 96.848% |
| CSL Limited | 15.76 Billion AUD | 100.001% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 99.93% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 99.947% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 98.449% |
| Dimerix Limited | -21.99 Million AUD | 99.562% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 99.491% |
| Hexima Limited | -2.22 Million AUD | 95.678% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 92.23% |
| Immuron Limited | -11.48 Million AUD | 99.162% |
| Immutep Limited | -122.18 Million AUD | 99.921% |
| Imugene Limited | -91.56 Million AUD | 99.895% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 98.403% |
| Memphasys Limited | 4.13 Million AUD | 102.327% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 99.437% |
| Noxopharm Limited | -2.31 Million AUD | 95.852% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 98.058% |
| Nyrada Inc. | -4.76 Million AUD | 97.982% |
| Orthocell Limited | -19.92 Million AUD | 99.517% |
| PharmAust Limited | -9.71 Million AUD | 99.009% |
| Patrys Limited | -2.24 Million AUD | 95.706% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 99.453% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 98.478% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 99.053% |
| PYC Therapeutics Limited | -65.76 Million AUD | 99.854% |
| Race Oncology Limited | -17.18 Million AUD | 99.44% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 99.482% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 97.167% |
| Starpharma Holdings Limited | -19.83 Million AUD | 99.515% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 99.909% |
| Tissue Repair Ltd | -16.44 Million AUD | 99.415% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 101.899% |